Use of phosphate-binding agents is associated with a lower risk of mortality.

[1]  M. Dorgan,et al.  Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis , 2013, The Lancet.

[2]  J. Carrero,et al.  COSMOS: the dialysis scenario of CKD-MBD in Europe. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  F. Dekker,et al.  Instrumental variable analysis. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  H. Morgenstern,et al.  Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  F. Kronenberg,et al.  Interaction of time-varying albumin and phosphorus on mortality in incident dialysis patients. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[6]  G. Remuzzi,et al.  Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. , 2011, Journal of the American Society of Nephrology : JASN.

[7]  A. Ortiz,et al.  Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  T. Vanel,et al.  Phosphate binders in a European haemodialysis population. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  Jorge B Cannata-Andía,et al.  Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  A. Hayen,et al.  Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. , 2011, JAMA.

[11]  K. Hruska,et al.  Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? , 2011, Kidney international. Supplement.

[12]  Florian Kronenberg,et al.  Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  S. Moe,et al.  50 Years of Research and Discovery in Chronic Kidney Disease and Mineral & Bone Disorder: The Central Role of Phosphate. , 2011, Kidney international.

[14]  B. Kestenbaum,et al.  Comparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patients. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[15]  J. New,et al.  Serum phosphate and mortality in patients with chronic kidney disease. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[16]  G. London,et al.  Mineral and bone disease pattern in elderly haemodialysis patients. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  A. Avenell,et al.  Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis , 2010, BMJ : British Medical Journal.

[18]  A. Slade,et al.  Efficacy and safety of SBR759, a new iron-based phosphate binder. , 2010, Kidney international.

[19]  Hilary F Luderer,et al.  Acute Phosphate Restriction Leads to Impaired Fracture Healing and Resistance to BMP-2 , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  C. Langman,et al.  Calcium in chronic kidney disease: myths and realities. Introduction. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[21]  S. Vukicevic,et al.  Ten-year experience with sevelamer and calcium salts as phosphate binders. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[22]  S. Jamal,et al.  Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[23]  M. P. Ruíz-Torres,et al.  High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. , 2010, Bone.

[24]  F. Port,et al.  International hemodialysis patient outcomes comparisons revisited: the role of practice patterns and other factors. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[25]  R. Pratt,et al.  Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy , 2009, Current medical research and opinion.

[26]  S. Sprague,et al.  Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. , 2009, Clinical nephrology.

[27]  A. Macleod,et al.  Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD) , 2009 .

[28]  M. E. Barnett,et al.  Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. , 2009, Clinical nephrology.

[29]  M. Wolf,et al.  Phosphorus binders and survival on hemodialysis. , 2009, Journal of the American Society of Nephrology : JASN.

[30]  B. Jensen,et al.  Phosphorus and Survival: Key Questions That Need Answers , 2009 .

[31]  Supplemental Tables,et al.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2009, Kidney international. Supplement.

[32]  H. Abboud,et al.  Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[33]  D. Rodríguez‐Puyol,et al.  Oral active vitamin D is associated with improved survival in hemodialysis patients. , 2008, Kidney international.

[34]  M. Wolf,et al.  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. , 2008, The New England journal of medicine.

[35]  L. Quarles,et al.  Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. , 2008, Kidney international.

[36]  F. Locatelli,et al.  Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). , 2008, Journal of nephrology.

[37]  J. Carrero,et al.  Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[38]  J. Craig,et al.  Meta-analysis: Vitamin D Compounds in Chronic Kidney Disease , 2007, Annals of Internal Medicine.

[39]  R. Foley.  Phosphorus comes of age as a cardiovascular risk factor. , 2007, Archives of internal medicine.

[40]  P. Raggi,et al.  Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. , 2007, Kidney international.

[41]  A. Luke,et al.  Increasing body mass index and obesity in the incident ESRD population. , 2006, Journal of the American Society of Nephrology : JASN.

[42]  T. Shigematsu,et al.  Sevelamer Hydrochloride and Calcium Bicarbonate Reduce Serum Fibroblast Growth Factor 23 Levels in Dialysis Patients , 2005, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[43]  W. Qunibi,et al.  Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. , 2005, Kidney international. Supplement.

[44]  P. Raggi,et al.  Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. , 2005, Arthritis and rheumatism.

[45]  H. Feldman,et al.  Haemodialysis prescription, adherence and nutritional indicators in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  R. Wolfe,et al.  Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2003, Journal of the American Society of Nephrology : JASN.

[47]  M. Wolf,et al.  Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. , 2003, The New England journal of medicine.

[48]  P. Raggi,et al.  Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. , 2002, Kidney international.

[49]  F. Locatelli,et al.  Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[50]  J. Cannata-Andía,et al.  The clinical impact of aluminium overload in renal failure. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[51]  W. Goodman.  Vascular calcification in chronic renal failure , 2001, The Lancet.

[52]  J. C. Andía.  Aluminium toxicity: its relationship with bone and iron metabolism. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[53]  J. Cannata Andía.  Aluminium toxicity: its relationship with bone and iron metabolism. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.